# Cnicus (Cnicus benedictus)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/cnicus
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** European
**Also Known As:** Cnicus benedictus, blessed thistle, holy thistle, St. Benedict's thistle, spotted thistle, blessed cardus, chardon bénit, cardo santo, Benediktenkraut

## Overview

Cnicus benedictus, or blessed thistle, contains the sesquiterpene lactone cnicin as its primary bioactive compound, which drives its [anti-inflammatory](/ingredients/condition/inflammation), antinociceptive, and antiproliferative effects. Cnicin inhibits NF-κB signaling and interacts with opioid pathways to reduce pain and suppress tumor cell proliferation in preclinical models.

## Health Benefits

• Antinociceptive effects: Preclinical rat studies show reduced formalin-induced pain at 150–300 mg/kg i.p. (PMID: 33628288, PMC7879793). • Antiproliferative activity: In vitro studies demonstrate inhibition of HeLa cervical cancer cells at concentrations of 0.1–1,000 µg/ml. • [Antiviral](/ingredients/condition/immune-support) activity: Cnicin shows dose-dependent inhibition of SARS-CoV-2 replication (IC50 1.18 µg/ml) in silico/in vitro studies. • Antiparasitic effects: Effective against Schistosoma trematodes in preclinical models. • Antibiotic properties: Essential oils extracted from the plant exhibit antibiotic effects.

## Mechanism of Action

The sesquiterpene lactone cnicin suppresses NF-κB transcription factor activation, reducing downstream [pro-inflammatory cytokine](/ingredients/condition/inflammation) production including TNF-α and IL-6. Cnicin also appears to interact with μ-opioid receptors and inhibits prostaglandin synthesis via COX pathway modulation, contributing to antinociceptive effects observed in rodent models. Antiproliferative activity against HeLa cells is attributed to cnicin-induced apoptosis and cell cycle arrest, likely via [mitochondrial](/ingredients/condition/energy) membrane potential disruption.

## Clinical Summary

Evidence for Cnicus benedictus in humans remains largely absent, with most data derived from preclinical animal and in vitro studies. Rat studies using intraperitoneal doses of 150–300 mg/kg demonstrated statistically significant reductions in formalin-induced pain responses (PMID: 33628288), though i.p. dosing limits direct human translation. In vitro antiproliferative effects against HeLa cervical cancer cells were observed across a wide concentration range (0.1–1,000 µg/ml), but no clinical trials have confirmed efficacy or safe effective doses in humans. The traditional use of blessed thistle as a digestive bitter and galactagogue predates modern evidence, and current scientific support is insufficient to make therapeutic claims.

## Nutritional Profile

Cnicus benedictus (blessed thistle) is primarily valued for its bioactive phytochemicals rather than macronutrient content. Key compounds include: • Sesquiterpene lactones: Cnicin is the dominant and most studied compound, typically present at 0.2–0.7% dry weight in aerial parts and leaves (up to 1.5% reported in some preparations); structurally a germacranolide-type lactone conferring bitter and bioactive properties. • Flavonoids: Luteolin, apigenin, and their glycosides (luteolin-7-glucoside, astragalin) present at trace to low mg/g levels; contribute [antioxidant activity](/ingredients/condition/antioxidant). • Lignans: Arctigenin and trachelogenin detected in extracts. • Polyacetylenes: Minor constituents with [antimicrobial](/ingredients/condition/immune-support) relevance. • Phenolic acids: Chlorogenic acid, caffeic acid, and protocatechuic acid identified chromatographically. • Essential oil components (0.3% in dried herb): Fenchone, p-cymene, citral, and sesquiterpene hydrocarbons. • Tannins: Approximately 2–3% tannin content contributing astringency. • Triterpenes: α- and β-amyrin identified. • Minerals: Limited quantitative data; iron, calcium, and potassium detected at low levels consistent with leafy botanicals; no standardized RDA-relevant quantities established. • Vitamins: Trace vitamin C reported; no substantial vitamin content documented. • Fiber: Present as structural plant material but not quantified for dietary purposes. • Protein/Fat/Carbohydrates: Not meaningfully characterized; used as a medicinal herb rather than a food source, so macronutrient profiling is largely absent from the literature. Bioavailability notes: Cnicin undergoes hydrolysis in alkaline gastrointestinal conditions, releasing the aglycone; oral bioavailability in humans is not well established. Bitter principles stimulate bile and gastric secretion, potentially enhancing absorption of co-ingested nutrients. Standardized extracts are typically normalized to cnicin content (minimum 0.2% per some European Pharmacopoeia references).

## Dosage & Preparation

Preclinical dosages include 150–300 mg/kg i.p. for antinociception in rats and 0.1–1,000 µg/ml for antiproliferation in vitro. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Cnicus benedictus is generally recognized as safe at typical culinary and herbal tea doses, but high doses may cause gastrointestinal irritation including nausea and vomiting due to the bitter sesquiterpene cnicin. Allergic reactions are possible in individuals sensitive to plants in the Asteraceae/Compositae family, including ragweed, chrysanthemums, and echinacea. Pregnant and breastfeeding women should avoid therapeutic doses, as uterine-stimulating effects have been reported traditionally, though human pharmacological data are lacking. Potential interactions exist with anticoagulant drugs and acid-suppressing medications due to its effects on gastric secretion, warranting caution with concurrent use.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted for Cnicus benedictus. The existing evidence is based on in vitro and animal studies. Notably, there is a lack of clinical support for its traditional use as a galactagogue (PMID: 33628288, PMC7879793).

## Historical & Cultural Context

Cnicus benedictus has a rich history in European folk medicine and is mentioned in Avicenna's Canon of Medicine from the 11th century. Traditionally, it has been used for digestive issues, as a galactagogue, and as a general tonic.

## Synergistic Combinations

Milk thistle, turmeric, ginger, black pepper, dandelion root

## Frequently Asked Questions

### What is the active compound in Cnicus benedictus?

The primary bioactive compound in Cnicus benedictus is cnicin, a sesquiterpene lactone found predominantly in the aerial parts of the plant. Cnicin is responsible for the herb's bitter taste and is believed to drive its anti-inflammatory, antinociceptive, and antiproliferative pharmacological activities through NF-κB inhibition and COX pathway modulation.

### Does Cnicus benedictus help with pain relief?

Preclinical rat studies have shown that intraperitoneal administration of Cnicus benedictus extract at 150–300 mg/kg significantly reduced formalin-induced pain responses (PMID: 33628288, PMC7879793), suggesting antinociceptive activity. However, no human clinical trials have confirmed these pain-relieving effects, and the intraperitoneal route used in animal studies does not directly correspond to oral supplementation in humans.

### Can Cnicus benedictus fight cancer cells?

In vitro studies have demonstrated that Cnicus benedictus extracts inhibit the proliferation of HeLa cervical cancer cells at concentrations ranging from 0.1 to 1,000 µg/ml, likely via cnicin-induced apoptosis and mitochondrial disruption. These findings are preliminary cell-culture data only, and no human or animal tumor studies have validated anticancer efficacy, so Cnicus benedictus cannot be considered a cancer treatment.

### Is Cnicus benedictus safe to take as a supplement?

At typical herbal doses used in teas and tinctures, Cnicus benedictus is generally considered safe for healthy adults, though doses above approximately 5 g may cause nausea and vomiting due to high cnicin content. Individuals with Asteraceae family allergies, those taking anticoagulants, and pregnant women should avoid supplemental doses due to risks of allergic cross-reactivity, bleeding interactions, and potential uterotonic effects respectively.

### What is Cnicus benedictus traditionally used for?

Blessed thistle has been used in European herbal medicine since the Middle Ages primarily as a digestive bitter to stimulate gastric acid and bile secretion, aiding digestion and appetite. It was also traditionally employed as a galactagogue to support breast milk production in nursing mothers, though modern clinical evidence for this use remains anecdotal and unverified by controlled trials.

### What does research show about Cnicus benedictus and viral infections?

In vitro and in silico studies indicate that cnicin, the primary active compound in Cnicus benedictus, demonstrates dose-dependent inhibition of SARS-CoV-2 replication with an IC50 of 1.18 µg/ml. However, these findings are preliminary laboratory-based results and have not yet been validated in human clinical trials. More research is needed to determine whether Cnicus benedictus would be effective for viral infections in real-world settings.

### Is Cnicus benedictus effective in the forms commonly available as supplements?

Most clinical evidence for Cnicus benedictus comes from isolated cnicin or whole plant extracts used in controlled laboratory and animal studies, often administered at specific doses (150–300 mg/kg in animal models). Commercial supplement forms vary widely in cnicin concentration and extraction methods, which can significantly affect bioavailability and efficacy. Standardized extracts are generally preferred over whole herb powders to ensure consistent active compound levels, though human bioavailability data is limited.

### Who should consider taking Cnicus benedictus based on current research?

Current evidence is strongest for individuals interested in traditional digestive and bile support, as Cnicus benedictus has been used historically for these purposes. Those experiencing mild pain or inflammation may find interest in preclinical antinociceptive findings, though human clinical trials are lacking. Anyone considering Cnicus benedictus for antiviral, antiproliferative, or pain-relief purposes should consult a healthcare provider, as existing evidence remains primarily laboratory-based rather than clinically validated in humans.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*